Navigation Links
Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance
Date:2/12/2008

lion, adjusted net income guidance of $67.7 - $74.5 million and basic adjusted income per common share guidance of $1.00 - $1.10.

Basic adjusted income per common share guidance for both the first quarter 2008 and full-year 2008 is reconciled below and is subject to the assumptions set forth therein.

Cephalon's management will discuss the company's fourth quarter and full year 2007 performance in a conference call with investors beginning at 5:00 p.m. U.S. EST on Tuesday, February 12, 2008. To participate in the conference call, dial +1-913-312-0669 and refer to conference code number 4647168. Investors can listen to the call live by logging on to the company's website at http://www.cephalon.com and clicking on "Investor Information," then "Webcast." The conference call will be archived and available to investors for one week after the call.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs close to 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide), AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), and ACTIQ(R). The company also markets nu
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2014)... 2014 The world-leading UV ... Kim, http://www.seoulviosys.com ) announced on September ... for the first time in the world. ... specific energy which deliver germicidal/pollutant-decomposing performance for ... food preservation applications. , The air purifier ...
(Date:9/2/2014)... , Sept. 2, 2014 Reportbuyer.com has ... Human Reproductive Technologies: Products and Global Markets ... AND OBJECTIVES The objective of the study ... the market for reproductive technologies and products. Markets ... The products in some markets are mature, while ...
(Date:9/2/2014)... 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Market Research ... Market Research Report on Global Ammonium Acetate Industry" ... - http://photos.prnewswire.com/prnh/20140902/141873 2014 ... is a professional and in-depth research report on ... Bicarbonate market. The report introduces Sodium Bicarbonate basic ...
(Date:9/2/2014)... Little Company of Mary Hospital in Evergreen Park, IL, ... Pavilion patient tower, which included the selection of 500 ... nurse’s lounge near the maternity ward. Established ... $180 million, four-year Campus Transformation project is culminating in ... Pavilion tower to the North Pavilion, as well as ...
Breaking Biology Technology:Human Reproductive Technologies: Products and Global Markets 2Human Reproductive Technologies: Products and Global Markets 3Human Reproductive Technologies: Products and Global Markets 4Human Reproductive Technologies: Products and Global Markets 5Human Reproductive Technologies: Products and Global Markets 6Human Reproductive Technologies: Products and Global Markets 7Human Reproductive Technologies: Products and Global Markets 8Human Reproductive Technologies: Products and Global Markets 9Human Reproductive Technologies: Products and Global Markets 10Human Reproductive Technologies: Products and Global Markets 11Human Reproductive Technologies: Products and Global Markets 12Human Reproductive Technologies: Products and Global Markets 13Human Reproductive Technologies: Products and Global Markets 14Human Reproductive Technologies: Products and Global Markets 15Human Reproductive Technologies: Products and Global Markets 16Human Reproductive Technologies: Products and Global Markets 17Sodium Bicarbonate Market & Ammonium Acetate Industry: China & Global Analysis 2Sodium Bicarbonate Market & Ammonium Acetate Industry: China & Global Analysis 3Sodium Bicarbonate Market & Ammonium Acetate Industry: China & Global Analysis 4Sodium Bicarbonate Market & Ammonium Acetate Industry: China & Global Analysis 5Tufftec® Lockers from Scranton Products Selected by Little Company of Mary Hospital Near Chicago to Create an Uplifting Environment 2Tufftec® Lockers from Scranton Products Selected by Little Company of Mary Hospital Near Chicago to Create an Uplifting Environment 3
... blood cells can clog arteries. Source: National Institutes of Health. ... , a gene therapy researcher, announced on Wednesday that it ... Research grant from the National Institutes of Health. , ,The ... for the treatment of anemia, a blood disorder that kills ...
... has been tested on lab mice with no apparent ... at a recent conference. Information supporting this conclusion was ... ,Strong was optimistic of the molecules ability to inhibit ... treatments, the companys proprietary EVade Ribonucleases are effective at ...
... up 31 percent for quarter ConjuGon CEO to ... Canadian cancer drug Wisconsin DOA buys Seritis software ... Web site GE Healthcare profits up ... 31 percent from the same quarter last year, the company has ...
Cached Biology Technology:Mirus receives $1.26 million SBIR grant to combat anemia 2Cancer treatment advances as trials show no harm to mice 2Tech Digest: whats moving in the Midwest 2Tech Digest: whats moving in the Midwest 3
(Date:9/2/2014)... rates between indigenous and non-indigenous women in Queensland, Australia, ... of stillbirth due to preventable causes, find researchers in ... BJOG: An International Journal of Obstetrics and Gynaecology ... from the Queensland Perinatal Data Collection and looked at ... to assess the differences in stillbirth rates over time ...
(Date:9/2/2014)... rupture through a U.S. suburb , Observations and ... in the hours and days after the August 24 ... the earthquake caused so much damage in the region, ... hosted by the American Geophysical Union. , ... Next Places to Direct Our Curiosity , Selecting ...
(Date:9/2/2014)... will present the prestigious Parker/Gentry Award to Mr. Rhett ... conservation awareness. The Parker/Gentry Award is given annually by ... organization whose efforts have had a significant impact on ... can serve as a model to others. , Rhett ... and conservation news website that draws more than 2 ...
Breaking Biology News(10 mins):Stillbirth gap closing between indigenous and non-indigenous women, shows Australian study 2Stillbirth gap closing between indigenous and non-indigenous women, shows Australian study 3This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2
... you ever met a cat that doesn't go crazy over ... the world don't respond to it at all, according to ... of Chemical & Engineering News, the weekly newsmagazine published by ... Catnip sensitivity is inherited, says Carolyn M. McDaniel, a veterinarian ...
... Florida researchers say they are a step closer to ... cancers before symptoms become apparent. , The findings, currently ... Sciences, involve introducing molecularly engineered strands of DNA into ... burst after they adhere to cancer proteins. , ...
... the gene responsible for controlling a first key step in ... in the journal Nature tomorrow (Thursday 27 October 2005). , ... take place once a sperm enters an egg, giving it ... reproducing animals. , The absence or mutation of this gene ...
Cached Biology News:Many cats unaffected by catnip, C&EN reports 2Scientists closer to new cancer detection method 2Scientists closer to new cancer detection method 3Scientists unpick genetics of first 15 minutes of life 2
The Cellject Elecroporator is suitable for all cell types including embryo, mammalian, plant, yeast and bacterial. Its has highly user-freindly programing and can be used remotely, for example in a l...
Request Info...
... Reverse Transcriptase (AMV RT) catalyzes the polymerization ... RNA:DNA hybrids (1). It requires a primer ... primers) as well as Mg2+ or Mn2+. ... activity. Both nonionic detergents and sulfhydryl compounds ...
Request Info...
Biology Products: